Opendata, web and dolomites

MetaTox-HS

Advanced Solutions for High Sensitivity Metabolism and Toxicity Assays

Total Cost €

0

EC-Contrib. €

0

Partnership

0

Views

0

 MetaTox-HS project word cloud

Explore the words cloud of the MetaTox-HS project. It provides you a very rough idea of what is the project "MetaTox-HS" about.

metabolism    trade    stages    scientific    serious    expensive    dominated    engineering    laboratory    full    enormous    write    pharmaceutical    est    sub    beneficiary    standard    doxycheck    industry    oct    drug    14    highlights    contract       labs    previously    innovative    criteria    businesses    components    biosciences    capex    uhs    solution    plate    instruments    completes    flexible    16    vivo    verification    final    sole    kits    jobs    reader    fluorescence    innovation    clear    scoring    2023    lux    synergy    hs    proof    electronic    consumable    opportunity    instrumentation    commercial    luxcel    mitoxpress    few    disease    accessible    requirement    creation    business    academia    models    polymer    bench    3bn    global    tests    translate    revenue    plan    readiness    critical    prototyped    demonstrated    manufacturing    3rd    boost    scientists    microfabrication    made    re    cell    position    metatox    either    consolidating    vitro    party    ltd    secures    job    320m    toxicity    market    submitted    5m    cum    13    bedside    platform    nanosensor    review    challenger    reg    pilot    performance    ambition    turnover    passing   

Project "MetaTox-HS" data sheet

The following table provides information about the project.

Coordinator
LUXCEL BIOSCIENCES LTD 

Organization address
address: BIOTRANSFER UNIT SUITE 3-32 BIOL
city: Cork
postcode: T12
website: www.luxcel.com

contact info
title: n.a.
name: n.a.
surname: n.a.
function: n.a.
email: n.a.
telephone: n.a.
fax: n.a.

 Coordinator Country Ireland [IE]
 Project website http://www.agilent.com/en/metatox-hs
 Total cost 1˙469˙333 €
 EC max contribution 1˙028˙533 € (70%)
 Programme 1. H2020-EU.2.1.5. (INDUSTRIAL LEADERSHIP - Leadership in enabling and industrial technologies - Advanced manufacturing and processing)
2. H2020-EU.2.1.3. (INDUSTRIAL LEADERSHIP - Leadership in enabling and industrial technologies - Advanced materials)
3. H2020-EU.2.3.1. (Mainstreaming SME support, especially through a dedicated instrument)
4. H2020-EU.2.1.2. (INDUSTRIAL LEADERSHIP - Leadership in enabling and industrial technologies – Nanotechnologies)
 Code Call H2020-SMEINST-2-2016-2017
 Funding Scheme SME-2
 Starting year 2017
 Duration (year-month-day) from 2017-06-01   to  2019-05-31

 Partnership

Take a look of project's partnership.

# participants  country  role  EC contrib. [€] 
1    LUXCEL BIOSCIENCES LTD IE (Cork) coordinator 1˙028˙533.00

Map

 Project objective

'Drug failure and high development cost (est. €2.3bn/new drug) has driven enormous growth in market need for scientific tests and models of disease, for researchers in academia, institutions and the pharmaceutical industry, that better translate from the bench (in vitro) to the bedside (in vivo). Critical tests are either not available, or only available on a few large, expensive dedicated instruments.

Luxcel Biosciences Ltd (LUX) has prototyped innovation that can now bring these high performance tests, to all laboratory scientists, for use on standard laboratory instrumentation already available in est. 20,000 labs (fluorescence plate reader), without requirement for CapEx.

LUX’s business innovation solution is a platform of low cost, flexible, easy to use and accessible in vitro cell metabolism and toxicity test kits and consumable products (MitoXpress UHS® and dOxycheck™) made possible through innovative synergy of LUX’s fluorescence nanosensor technology, together with advanced polymer microfabrication and electronic engineering.

MetaTox-HS project, completes the final stages of development, verification, pilot process and manufacturing readiness, together with dissemination and exploitation activities, to bring the full product solution to market and secures EU based revenue and job creation; 13 new jobs and €14.5m cum turnover by 2023, consolidating LUXCEL’s EU position (2 YR), and ambition to become a serious #2 challenger in this est. €320m accessible US and global market (5 YR), currently dominated by US businesses.

Proposal previously submitted Oct ’16, scoring highly, passing all three criteria. Following a full commercial review LUXCEL has taken a sole beneficiary role, with key enabling technology provided through 3rd party sub-contract. A full re-write highlights: clear product components, demonstrated proof-of-concept, well-defined market opportunity and strong commercial plan to boost growth. '

Are you the coordinator (or a participant) of this project? Plaese send me more information about the "METATOX-HS" project.

For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.

Send me an  email (fabio@fabiodisconzi.com) and I put them in your project's page as son as possible.

Thanks. And then put a link of this page into your project's website.

The information about "METATOX-HS" are provided by the European Opendata Portal: CORDIS opendata.

More projects from the same programme (H2020-EU.2.1.5.;H2020-EU.2.1.3.;H2020-EU.2.3.1.;H2020-EU.2.1.2.)

NAS (2018)

Nexilis augmentation system

Read More  

Gri3D (2018)

The industrialization and market entry of a novel bioengineered hydrogel grid to standardize stem cell cultures for precision medicine.

Read More  

CGM (2018)

A next generation nano media tailored to capture and recycle hazardous micropollutants in contaminated industrial wastewater.

Read More